Harrow Licenses Rights to Five Drugs to Apotex for Canada

Harrow reported Feb. 15 that it had licensed to Apotex exclusive marketing and distribution rights to Verkasia and over-the-counter Cationorm Plus in the Canadian market. In addition, Apotex will pursue market approval in Canada for Vevye, Iheezo, and Zerviate under the deal.

Apotex is a leading Canadian pharmaceutical company that employs almost 7 thousand people worldwide, with medicines accessible to patients in more than 75 countries.

The move marks Nashville, Tennessee-based Harrow’s entry into the Canadian market through the partnership. No financial details were released.

Verkasia (cyclosporine ophthalmic emulsion) 0.1% is a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis in children.

Cationorm Plus is a preservative-free emulsion for the treatment of dry eye symptoms and the signs and symptoms of ocular allergy.

Vevye (cyclosporine ophthalmic solution) 0.1% is a water-free vehicle (perfluorobutylpentane) based on semifluorinated alkanes that is indicated to treat the signs and symptoms of dry eye.

iHeezo (chloroprocaine hydrochloride ophthalmic gel) 3% a single-use, low-viscosity gel indicated for ocular surface anesthesia.

Zerviate (cetirizine ophthalmic solution) 0.24% is a histamine-1 (H1) receptor antagonist indicated for the treatment of ocular itching associated with allergic conjunctivitis.